Amyloid beta 42 (Abeta42) Antibody

Background

Abeta42 is a 42-amino acid peptide that differs from Aβ40 by two additional residues at the C-terminal end, resulting in increased hydrophobicity and a greater propensity to aggregate into oligomers and fibrils. Aβ42 is a major component of the amyloid plaques found in Alzheimer’s disease, playing a critical role in its pathogenesis. Its aggregation disrupts neuronal membranes, induces oxidative stress, and triggers inflammatory responses, leading to synaptic dysfunction and neuronal death. Aβ42 is considered more neurotoxic than Aβ40 due to its higher aggregation potential and its ability to form soluble oligomers that impair synaptic signaling. The ratio of Aβ42 to Aβ40 in cerebrospinal fluid is a key biomarker for diagnosing and monitoring Alzheimer’s disease progression. Research is ongoing to understand the mechanisms of Aβ42 aggregation and its interactions with tau proteins, with the goal of developing therapeutic strategies targeting Aβ42 to mitigate Alzheimer’s-related neurodegeneration.